Bart Tarbet

Dr. Bart Tarbet

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MSMichael Dominic Sacco
Michael Dominic Sacco
CMChunlong Ma
Chunlong Ma
PLPanagiotis Lagarias
Panagiotis Lagarias
AGAng Gao
Ang Gao
JTJulia Alma Townsend
Julia Alma Townsend
JWJun Wang
Jun Wang
X-ray crystal structures of SARS-CoV-2 M pro with dual inhibitors provide a new direction for the designing of COVID-19 antivirals.

1 May 2017 in Antiviral Research
Verified
Journal Article
Closed access
WTWenqian Tao
Wenqian Tao
BHBrett L. Hurst
Brett L. Hurst
ASAkhilesh Kumar Shakya
Akhilesh Kumar Shakya
JUJasim Uddin
Jasim Uddin
RIRohan S.J. Ingrole
Rohan S.J. Ingrole
HGHarvinder Singh Gill
Harvinder Singh Gill

1 October 2015 in Cell
Verified
Journal Article
Closed access
MSMichael D. Swanson
Michael D. Swanson
DBDaniel M. Boudreaux
Daniel M. Boudreaux
LSLoïc Salmon
Loïc Salmon
JCJeetender Chugh
Jeetender Chugh
HWHarry C. Winter
Harry C. Winter
DMDavid M. Markovitz
David M. Markovitz

1 December 1988 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RMR K Mehra
R K Mehra
BTBart Tarbet
Bart Tarbet
WGW R Gray
W R Gray
DWD R Winge
D R Winge
Cellular resistance to heavy metal cytotoxicity in most species is mediated by the binding of metal ions either to a cysteine-rich polypeptide in the metallothionein family or to short cysteine-containing gamma-glutamyl peptides. One of these metal binding systems has been found in most organisms studied. However, the yeast Candida (Torulopsis) glabrata expresses both metallothionein and the gamma-glutamyl peptides for metal detoxification, and each system is regulated in a metal-specific manner. Exposure of C. glabrata to copper salts stimulates formation of two metallothionein-like polypeptides with a cysteine content of 30 mol% and the repeated sequence Cys-Xaa-Cys. The cells synthesize gamma-glutamyl peptides upon exposure to cadmium salts. Penta- and tetrapeptides that form a cadmium-thiolate cluster in a peptide oligomer containing labile sulfur are synthesized.

1 January 2010 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
DSDonald F. Smee
Donald F. Smee
BHBrett L. Hurst
Brett L. Hurst
MWMin-Hui Wong
Min-Hui Wong
KBKevin W. Bailey
Kevin W. Bailey
BTBart Tarbet
Bart Tarbet
YFYousuke Furuta
Yousuke Furuta
Favipiravir (T-705 [6-fluoro-3-hydroxy-2-pyrazinecarboxamide]) and oseltamivir were combined to treat influenza virus A/NWS/33 (H1N1), A/Victoria/3/75 (H3N2), and A/Duck/MN/1525/81 (H5N1) infections. T-705 alone inhibited viruses in cell culture at 1.4 to 4.3 μM. Oseltamivir inhibited these three viruses in cells at 3.7, 0.02, and 0.16 μM and in neuraminidase assays at 0.94, 0.46, and 2.31 nM, respectively. Oral treatments were given twice daily to mice for 5 to 7 days starting, generally, 24 h after infection. Survival resulting from 5 days of oseltamivir treatment (0.1 and 0.3 mg/kg/day) was significantly better in combination with 20 mg/kg of body weight/day of T-705 against the H1N1 infection. Treatment of the H3N2 infection required 50 mg/kg/day of oseltamivir for 7 days to achieve 60% protection; 25 mg/kg/day was ineffective. T-705 was ≥70% protective at 50 to 100 mg/kg/day but inactive at 25 mg/kg/day. The combination of inhibitors (25 mg/kg/day each) increased survival to 90%. The H5N1 infection was not benefited by treatment with oseltamivir (≤100 mg/kg/day for 7 days). T-705 was 30 to 70% protective at 25 to 100 mg/kg/day. Survival improved slightly with combination treatments. Increased activity was seen against H5N1 infection by starting treatments 2 h before infection. Oseltamivir was ineffective at ≤40 mg/kg/day. T-705 was 100% protective at 40 and 80 mg/kg/day and inactive at 20 mg/kg/day. Combining ineffective doses (20 mg/kg/day of T-705 and 10 to 40 mg/kg/day of oseltamivir) afforded 60 to 80% protection and improved body weights during infection. Thus, synergistic responses were achieved with low doses of T-705 combined with oseltamivir. These compounds may be viable candidates for combination treatment of human influenza infections.

1 July 2016 in Antiviral Research
Verified
Journal Article
Closed access
DSDonald F. Smee
Donald F. Smee
WEW. Joseph Evans
W. Joseph Evans
KNK.C. Nicolaou
K.C. Nicolaou
BTBart Tarbet
Bart Tarbet
CDCraig W. Day
Craig W. Day